Universität zu Köln

Berghoff, Anna S., Bellosillo, Beatriz, Caux, Christophe ORCID: 0000-0003-2438-833X, de Langen, Adrianus, Mazieres, Julien, Normanno, Nicola ORCID: 0000-0002-7158-2605, Preusser, Matthias, Provencio, Mariano, Rojo, Federico, Wolf, Jurgen and Zielinski, Christoph C. (2019). Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion. ESMO Open, 4 (3). LONDON: BMJ PUBLISHING GROUP. ISSN 2059-7029

Full text not available from this repository.

Abstract

The introduction of targeted treatments and more recently immune checkpoint inhibitors (ICI) to the treatment of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected patients. For patients with oncogene-addicted metastatic NSCLC harbouring an epidermal growth factor receptor (EGFR) or v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) mutation or an anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene alteration (translocation, fusion, amplification) mutation-specific tyrosine kinase inhibitors (TKI) are already first-line standard treatment, while targeted treatment for other driver mutations affecting MET, RET, human epidermal growth factor receptor (HER) 2, tropomyosin receptor kinases (TRK) 1-3 and others are currently under investigation. The role of ICI in these patient subgroups is currently under debate. This article summarises a round-table discussion organised by ESMO Open in Vienna in July 2018. It reviews current clinical data on ICI treatment in patients with metastatic oncogene-addicted NSCLC and discusses molecular diagnostic assessment, potential biomarkers and radiological methods for response evaluation of ICI treatment. The round-table panel concluded ICI should only be considered in patients with oncogene-addicted NSCLC after exhaustion of effective targeted therapies and in some cases possibly after all other therapies including chemotherapies. More clinical trials on combination therapies and biomarkers for ICI therapy based on the specific differing characteristics of oncogene-addicted NSCLC need to be conducted.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Berghoff, Anna S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bellosillo, Beatriz UNSPECIFIED UNSPECIFIED UNSPECIFIED Caux, Christophe UNSPECIFIED orcid.org/0000-0003-2438-833X UNSPECIFIED de Langen, Adrianus UNSPECIFIED UNSPECIFIED UNSPECIFIED Mazieres, Julien UNSPECIFIED UNSPECIFIED UNSPECIFIED Normanno, Nicola UNSPECIFIED orcid.org/0000-0002-7158-2605 UNSPECIFIED Preusser, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Provencio, Mariano UNSPECIFIED UNSPECIFIED UNSPECIFIED Rojo, Federico UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Jurgen UNSPECIFIED UNSPECIFIED UNSPECIFIED Zielinski, Christoph C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-138313
DOI:	10.1136/esmoopen-2019-000498
Journal or Publication Title:	ESMO Open
Volume:	4
Number:	3
Date:	2019
Publisher:	BMJ PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	2059-7029
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GROWTH-FACTOR RECEPTOR; LIGAND 1 EXPRESSION; ACQUIRED-RESISTANCE; EGFR MUTATION; T790M STATUS; OPEN-LABEL; ATEZOLIZUMAB; OSIMERTINIB; NIVOLUMAB; DOCETAXEL Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13831